Fibrogen announces analyses from roxadustat global phase 3 program at american society of nephrology kidney week 2021

San francisco, oct. 25, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen), today announced that analyses from the global phase 3 roxadustat clinical program will be presented at the american society of nephrology kidney week 2021 taking place virtually november 4 - 7, 2021. a total of 18 presentations will be presented by fibrogen, or its collaboration partners astrazeneca and astellas pharma, inc., at this year's meeting. eleven of the presentations are related to phase 3 studies of roxadustat for the treatment of anemia associated with ckd. an additional seven presentations are related to ckd anemia epidemiology and disease state which outline the burden of anemia on ckd patients and the continued unmet medical need for innovative therapies.
FGEN Ratings Summary
FGEN Quant Ranking